3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Glioma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Laryngeal Neoplasms
1
Histiocytic Sarcoma
1
Hematologic Neoplasms
1
Erdheim-Chester Disease
1
Craniopharyngioma
1
Interventions
trametinib
2
dabrafenib
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
sargramostim
1
cobimetinib
1
cabozantinib
1
atezolizumab
1
aldesleukin
1
Vemurafenib
1
Trastuzumab
1
Tamoxifen
1
Semaxinib
1
Radiotherapy
1
Paclitaxel
1
Gefitinib
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Vemurafenib
×
CNS
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled